Skip to main content

Market Overview

MedTech Round Up: Update On Johnson & Johnson, Becton Dickinson, Labcorp, Second Sight Medical, Biocept

Share:
MedTech Round Up: Update On Johnson & Johnson, Becton Dickinson, Labcorp, Second Sight Medical, Biocept

Johnson & Johnson's (NYSE: JNJ) Vision segment has won FDA approval for the first contact lenses designed to reshape the cornea curve and help treat the progression of myopia in children.

  • Designed to be worn overnight, the Acuvue Abiliti orthokeratology lenses are specifically fitted to match each eye, including people with and without astigmatism.
  • Price Action: JNJ shares are trading 1.41% higher at $170.57 during the market session on the last check Thursday.

Becton Dickinson and Co (NYSE: BDX) has received a CE mark for its HPV screening from at-home self-collected vaginal samples using BD Onclarity HPV Assay.

  • The assay can detect and identify 14 high-risk human papillomavirus (HPV) types in a single analysis and provide genotyping information.
  • Price Action: BDX shares are trading 1.33% higher at $244.85 during the market session on the last check Thursday.

The FDA has granted Emergency Use Authorization for its Pixel by Labcorp (NYSE: LH) COVID-19 PCR test home collection kit for ages 2-17.

  • The authorization expands the use of Pixel by Labcorp to children and adolescents two years of age and older.
  • Price Action: LH shares are trading 1.97% higher at $277.26 during the market session on the last check Thursday.

Second Sight Medical Products Inc (NASDAQ: EYES) has received year three funding for its Orion Trial from the National Institutes of Health (NIH).

Biocept Inc (NASDAQ: BIOC) has entered into a controlled equity offering with Cantor Fitzgerald & Co to sell up to $25 million of its common stock.

  • It reported a Q1 EPS of $0.19, a turnaround from a $(1.06) loss a year ago. Revenues of $17.7 million compared to $1.4 million in Q1 2020 were well above the consensus of $13.7 million.
  • The increase is attributable to higher RT-PCR COVID-19 testing.
  • Price Action: BIOC shares are trading 9.9% lower at $4.29 during the market session on the last check Thursday.
 

Related Articles (JNJ + BIOC)

View Comments and Join the Discussion!

Posted-In: Medical TechnologyEarnings News Penny Stocks Health Care Offerings FDA General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com